Table 3. Percentage Growth of Cancer Cells Treated with Compounds 16a–e at a Dose of 10 μM.
| compound
code |
|||||
|---|---|---|---|---|---|
| cell lines | 16a | 16b | 16c | 16d | 16e |
| Leukemia | |||||
| CCRF-CEM | 80.22 | 88.04 | 97.38 | 101.53 | 101.57 |
| HL-60 (TB) | 98.35 | 99.55 | 99.05 | 100.80 | 99.82 |
| K-562 | 44.82 | 54.78 | 77.07 | 92.78 | 75.30 |
| MOLT-4 | 64.33 | 74.19 | 88.12 | 92.44 | 92.11 |
| RPMI-8226 | 62.34 | 75.07 | 88.56 | 98.70 | 88.16 |
| SR | 68.10 | 80.58 | 98.05 | 92.78 | 97.00 |
| Non-Small Cell Lung Cancer | |||||
| A549/ATCC | 59.15 | 72.72 | 87.91 | 95.65 | 92.18 |
| EKVX | 70.09 | 78.49 | 90.97 | 95.58 | 91.78 |
| HOP-62 | 68.97 | 77.78 | 94.29 | 97.31 | 94.75 |
| HOP-92 | 70.15 | 87.22 | 83.00 | 95.10 | 86.33 |
| NCI-H226 | 73.55 | 82.19 | 87.96 | 100.50 | 90.45 |
| NCI-H23 | 67.72 | 82.43 | 86.05 | 92.43 | 96.24 |
| NCI-H322M | 89.94 | 94.29 | 102.92 | 98.57 | 102.78 |
| NCI-H460 | 73.33 | 86.16 | 97.71 | 104.41 | 99.39 |
| NCI-H522 | 58.18 | 67.43 | 76.39 | 85.73 | 82.98 |
| Colon Cancer | |||||
| COLO 205 | 76.58 | 95.47 | 104.94 | 110.37 | 112.22 |
| HCC-2998 | 84.49 | 96.41 | 88.39 | 104.18 | 99.67 |
| HCT-116 | 39.67 | 56.75 | 84.36 | 94.87 | 86.28 |
| HCT-15 | 59.49 | 70.77 | 86.89 | 100.71 | 95.70 |
| HT29 | 36.02 | 49.22 | 84.27 | 100.63 | 87.22 |
| KM12 | 75.02 | 86.71 | 93.93 | 102.69 | 100.52 |
| SW-620 | 72.04 | 83.60 | 95.19 | 105.74 | 95.41 |
| CNS Cancer | |||||
| SF-268 | 69.46 | 77.34 | 89.71 | 94.39 | 91.22 |
| SF-295 | 78.46 | 87.77 | 90.64 | 97.51 | 93.95 |
| SF-539 | 90.55 | 100.79 | 104.33 | 100.38 | 102.47 |
| SNB-19 | 85.08 | 89.96 | 85.98 | 87.01 | 89.85 |
| SNB-75 | 71.88 | 83.86 | 76.68 | 91.74 | 96.08 |
| U251 | 82.30 | 82.13 | 92.86 | 91.07 | 94.12 |
| Melanoma | |||||
| LOX IMVI | 79.81 | 88.84 | 92.97 | 97.67 | 97.29 |
| MALME-3M | 81.71 | 87.68 | 92.72 | 111.17 | 99.40 |
| M14 | 76.03 | 85.48 | 98.93 | 109.01 | 101.58 |
| MDA-MB-435 | 78.90 | 88.88 | 97.65 | 103.80 | 106.47 |
| SK-MEL-2 | 82.90 | 93.09 | 96.90 | 104.38 | 99.20 |
| SK-MEL-28 | 95.61 | 101.39 | 104.95 | 114.70 | 113.92 |
| SK-MEL-5 | 94.24 | 97.21 | 99.07 | 98.92 | 99.04 |
| UACC-257 | 85.54 | 97.67 | 97.50 | 102.49 | 103.32 |
| UACC-62 | 63.88 | 65.22 | 66.32 | 75.93 | 78.38 |
| Ovarian Cancer | |||||
| IGROV1 | 62.55 | 67.05 | 80.82 | 85.77 | 79.66 |
| OVCAR-3 | 79.31 | 95.23 | 97.80 | 107.31 | 101.14 |
| OVCAR-4 | 63.65 | 79.33 | 83.64 | 102.88 | 96.31 |
| OVCAR-5 | 82.07 | 88.79 | 88.56 | 98.18 | 98.89 |
| OVCAR-8 | 83.79 | 90.09 | 95.46 | 100.69 | 98.81 |
| NCI/ADR-RES | 58.94 | 70.83 | 76.67 | 95.63 | 79.68 |
| SK-OV-3 | 80.79 | 98.18 | 91.41 | 99.94 | 93.62 |
| Renal Cancer | |||||
| 786–0 | 79.22 | 87.65 | 96.01 | 97.77 | 97.79 |
| A498 | 88.93 | 102.44 | 99.79 | 102.85 | 104.93 |
| ACHN | 79.63 | 89.56 | 95.55 | 98.78 | 100.18 |
| CAKI-1 | 46.90 | 54.08 | 68.21 | 70.13 | 63.20 |
| RXF 393 | 69.66 | 92.66 | 80.83 | 92.48 | 92.58 |
| SN12C | 69.96 | 81.35 | 92.08 | 99.09 | 94.48 |
| TK-10 | 92.06 | 97.01 | 102.72 | 105.97 | 109.46 |
| UO-31 | 48.28 | 56.35 | 70.33 | 72.62 | 65.87 |
| Prostate Cancer | |||||
| PC-3 | 43.51 | 55.82 | 75.31 | 79.50 | 70.70 |
| DU-145 | 83.54 | 99.22 | 99.00 | 106.99 | 103.63 |
| Breast Cancer | |||||
| MCF7 | 62.37 | 75.94 | 98.76 | 93.65 | 98.51 |
| MDA-MB-231/ATCC | 81.72 | 89.25 | 93.93 | 94.75 | 94.68 |
| HS 578T | 89.25 | 93.87 | 93.24 | 95.37 | 94.21 |
| BT-549 | 100.02 | 99.28 | 105.31 | 105.13 | 110.56 |
| T-47D | 49.54 | 64.16 | 85.76 | 86.09 | 81.52 |
| MDA-MB-468 | 81.40 | 91.24 | 95.45 | 114.03 | 105.94 |
| mean % growth | 73.10 | 83.11 | 90.79 | 97.49 | 94.51 |